“…The veto-like (forbidding) activity of MSCs (Potian et al, 2003;Tscherning and Claesson, 1993) inhibits T-cell proliferation (Bartholomew et al, 2002;Bocelli-Tyndall et al, 2007;Di Nicola et al, 2002;Klyushnenkova et al, 2005) via induction of T-cell quiescence upon blockade into G0/G1 (Glennie et al, 2005) and downregulation of the T-cell activation markers CD25, CD38, and CD69 (Groh et al, 2005;Le Blanc et al, 2004) and of IL-2 production (Park et al, 2011). MSCs also inhibit Th17 differentiation from both naïve and memory T cell precursors in vitro, as well as preventing the efflux of naturally occurring Th17 cells derived from inflammation sites in vivo (Duffy et al, 2011).…”